3/4
07:30 am
ngen
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
Medium
Report
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
2/18
07:57 am
ngen
NervGen Pharma to Participate at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
NervGen Pharma to Participate at Upcoming Investor Conferences [Yahoo! Finance]
2/18
07:30 am
ngen
NervGen Pharma to Participate at Upcoming Investor Conferences
Low
Report
NervGen Pharma to Participate at Upcoming Investor Conferences
2/12
04:15 pm
ngen
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
Low
Report
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
2/11
07:31 am
ngen
NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium [Yahoo! Finance]
Low
Report
NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium [Yahoo! Finance]
2/11
07:28 am
ngen
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium [Canadian Business Journal (Canada)]
Low
Report
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium [Canadian Business Journal (Canada)]
2/11
07:00 am
ngen
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
Low
Report
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
2/9
08:21 am
ngen
NervGen Pharma appoints new president & CEO [Seeking Alpha]
Low
Report
NervGen Pharma appoints new president & CEO [Seeking Alpha]
2/9
07:00 am
ngen
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
Medium
Report
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
1/20
07:28 am
ngen
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing [Canadian Business Journal (Canada)]
Low
Report
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing [Canadian Business Journal (Canada)]
1/20
07:00 am
ngen
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
Medium
Report
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
1/8
06:30 am
ngen
NervGen Pharma Begins Trading on Nasdaq Today
High
Report
NervGen Pharma Begins Trading on Nasdaq Today